Literature DB >> 29277762

Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.

Hiroaki Saito1, Yusuke Kono2, Yuki Murakami2, Yuji Shishido2, Hirohiko Kuroda2, Tomoyuki Matsunaga2, Yoji Fukumoto2, Tomohiro Osaki2, Keigo Ashida2, Yoshiyuki Fujiwara2.   

Abstract

BACKGROUND: A recent study demonstrated that immune-checkpoint molecules are associated with tumoral immune evasion.
MATERIALS AND METHODS: Programmed cell death protein 1 (PD-1) expression on CD4+ and CD8+ T-cells obtained from gastric cancer tissue was evaluated by multicolor flow cytometry. Immunohistochemical staining was also performed to evaluate programmed cell death ligand-1 (PD-L1) expression on gastric cancer cells.
RESULTS: There were statistically significant correlations between PD-L1 expression and age, histology, tumor size, depth of invasion, lymph node metastasis, lymphatic vessel invasion, venous invasion, and disease stage. The 5-year survival rates of patients with and without PD-L1-positive tumors were 48.9% and 80.7%, respectively, and the difference was statistically significant. Multivariate analysis indicated that PD-L1 expression was an independent prognostic indicator. The frequency of PD-1-positive CD4+ and CD8+ T-cells from gastric cancer tissue with PD-L1 expression was significantly more than that from gastric cancer tissue without PD-L1 expression.
CONCLUSION: PD-L1 expression was related to a poor prognosis in patients with gastric cancer. Furthermore, PD-1 expression on T-cells was up-regulated in patients with tumors with PD-L1 expression. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastric cancer; PD-1; PD-L1; T-cells

Mesh:

Substances:

Year:  2018        PMID: 29277762     DOI: 10.21873/anticanres.12197

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  miR-502-5p affects gastric cancer progression by targeting PD-L1.

Authors:  Wendao You; Xiaoyu Liu; Yang Yu; Chen Chen; Yujia Xiong; Yiting Liu; Yibin Sun; Chenhuan Tan; Hanshuo Zhang; Yadong Wang; Rui Li
Journal:  Cancer Cell Int       Date:  2020-08-15       Impact factor: 5.722

2.  Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.

Authors:  Tian Yun; Sunan Wang; Bo Jiang; Changsong Wang; Nianlong Meng; Xutao Yuan; Yangkun Wang
Journal:  J Oncol       Date:  2020-10-13       Impact factor: 4.375

3.  MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.

Authors:  Lingyu Qian; Fangcen Liu; Yanhong Chu; Qingqing Zhai; Xiao Wei; Jie Shao; Rutian Li; Qiuping Xu; Lixia Yu; Baorui Liu; Qin Liu
Journal:  Cancer Manag Res       Date:  2020-11-27       Impact factor: 3.989

Review 4.  Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.

Authors:  Rodolfo Daniel Cervantes-Villagrana; Damaris Albores-García; Alberto Rafael Cervantes-Villagrana; Sara Judit García-Acevez
Journal:  Signal Transduct Target Ther       Date:  2020-06-18

5.  Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.

Authors:  Jingwei Liu; Hao Li; Liping Sun; Yuan Yuan; Chengzhong Xing
Journal:  Biomed Res Int       Date:  2020-06-06       Impact factor: 3.411

6.  Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.

Authors:  Rong Yan; Xiaobing Yang; Xiaolei Wang; Bin Wang; Youcai Zhao; Wenbin Huang; Wei Zhao; Lizhou Jia
Journal:  Med Sci Monit       Date:  2019-09-14

7.  PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.

Authors:  Lingyu Tian; Jiaqiang Ma; Lijie Ma; Bohao Zheng; Longzi Liu; Danjun Song; Yining Wang; Zhao Zhang; Qiang Gao; Kang Song; Xiaoying Wang
Journal:  World J Surg Oncol       Date:  2020-11-23       Impact factor: 2.754

8.  Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression.

Authors:  Nghiem Xuan Hoan; Pham Thi Minh Huyen; Mai Thanh Binh; Ngo Tat Trung; Dao Phuong Giang; Bui Thuy Linh; Dang Thi Ngoc Dung; Srinivas Reddy Pallerla; Peter G Kremsner; Thirumalaisamy P Velavan; Mai Hong Bang; Le Huu Song
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

9.  Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.

Authors:  Dong Hyun Kim; Go Eun Bae; Kwang Sun Suh; David Ryuman; Kyu Sang Song; Ju Seok Kim; Sang-Il Lee; Min-Kyung Yeo
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 10.  Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.

Authors:  Peixin Dong; Ying Xiong; Junming Yue; Sharon J B Hanley; Hidemichi Watari
Journal:  Front Oncol       Date:  2018-09-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.